Area riservata



Biochimica del cervello

Alizé Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome
Scritto da Genetics News From Medical News Today   
BiochimicaResults from the randomized, double blind and placebo-controlled Phase II trial show significant improvements in hyperphagia-related behavior, a key therapeutic objective in Prader-Willi Syndrome.
Fonte: Genetics News From Medical News Today
 

Aggiungi commento


Codice di sicurezza
Aggiorna